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DEFINITION AND BIOLOGY OF NO-REFLOW
The no-reflow phenomenon is the inability to perfuse a
portion of the myocardium after re-establishment of pa-
tency of a previously occluded epicardial coronary artery
(1–3). This phenomenon has been described in experimen-
tal animal models in which the coronary artery is occluded
with a mechanical occluder or snare (1). In animal models
no-reflow has been detected by using the fluorescent dye
Thioflavin S that stains endothelium receiving flow, radio-
active microspheres, carbon black, echocardiographic con-
trast, and magnetic resonance imaging (MRI) techniques.
The phenomenon also has been observed in humans after
reperfusion therapy for acute myocardial infarction (MI) in
which the occlusion is thrombus mediated, and it has been
measured using myocardial contrast echocardiography, nu-
clear tracers, and MRI (4–6). Perfusion at the tissue level
can be severely compromised even when the epicardial
coronary artery appears to be fully patent by coronary
angiography.
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In previous experimental studies we observed the devel-
opment of the no-reflow phenomenon when the proximal
coronary artery was occluded for 90 min or 3 hrs but not 40
min, followed by reperfusion therapy (1). In our models the
zone of no-reflow is usually confined to areas of necrotic
myocardium (1,2,7–9). There is a tight coupling between
infarct size and no-reflow. Outside the zone of no-reflow,
there may be an area that is necrotic but that contains an
infarct that can be reperfused. Although there is ongoing
discussion whether reducing no-reflow can then reduce
infarct size, in most of our analyses, myocardial cell death
occurs before the disruption of the microvasculature. Thus,
in our opinion, no-reflow probably does not exacerbate
myocardial cell death but occurs after the myocytes in the
area are already dead. This does not mean that no-reflow
should be ignored. A large zone of no-reflow may impede
the ability of the infarct to heal and prevent delivery of
pharmaceutical agents (such as anti-arrhythmics) into the
infarct zone. Recently, we observed that a large area of
no-reflow predicts worse infarct expansion and left ventric-
ular (LV) dilation (Reffelmann T, Hale SL, Dow JS, Kloner
RA, submitted for publication). In humans, the no-reflow
phenomenon predicts worse outcome in the post-MI pa-
tient (5,10).
In this issue of the Journal, Kunichika et al. (11) clearly
show that quantitative myocardial contrast echocardiogra-
phy (QMCE) is a useful non-invasive tool for measuring
myocardial perfusion and diagnosing and quantitating no-
reflow in real time. Myocardial blood flow velocity is
measured by the rapid destruction of echo contrast micro-
bubbles using ultrasound and then determining the rate at
which they refill the myocardium. Findings with QMCE
paralleled their measures of regional myocardial blood flow
made with fluorescent microspheres. The beauty of the echo
contrast technique is that it can be used repeatedly to
measure the success (or failure) of myocardial perfusion by a
non-invasive technique. It can be used to track perfusion
over time, measuring the ability of pharmacologic therapy to
affect perfusion of the tissue.
THERAPY FOR NO-REFLOW
A reduction in the size of the anatomic zone of no-reflow
might limit infarct expansion, enhance healing, and reduce
long-term LV dilation. In our models, any agent that
reduces MI size will secondarily reduce no-reflow. We have
observed this coupling with agents such as cariporide,
preconditioning (12), and hypothermia (13). We have not
observed any benefit of thrombolytic agents on infarct size
or no-reflow in a mechanical (non-thrombotic) model of
coronary artery occlusion. In the present study by Kunichika
et al. (11), a fascinating observation was made. Tirofiban, a
platelet glycoprotein (GP) IIb/IIIa inhibitor, reduced in-
farct size and no-reflow in a non-thrombotic coronary
occlusion model in the dog. Previous studies in patients
with thrombotic coronary occlusions have shown that GP
IIb/IIIa inhibitors can enhance reperfusion as would be
expected in the setting of a thrombus. GP IIb/IIIa inhibi-
tors were shown to decrease coronary thrombus, improve
TIMI flow grade, enhance epicardial reperfusion when
combined with thrombolysis, improve 30-day clinical out-
comes post MI, speed resolution of ST-segment elevation,
and in one study of elective percutaneous coronary inter-
vention improve coronary artery flow reserve and myocardial
blush grade. The later two findings support improved
microvascular reperfusion (14–17). Kunichika et al.’s (11)
observation has an important implication related to the role
of platelets in no-reflow. No-reflow in the setting of a
thrombotic occlusion may be related in part to micro-
emboli, and platelet aggregates could play a significant role
(18). However, the exact cause of no-reflow in a non-
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the †Heart Institute, Good Samaritan Hospital and ‡Division of Cardio-
vascular Medicine, Keck School of Medicine, University of Southern California, Los
Angeles, California. Jonathan R. Lindner, MD, FACC, acted as guest editor for this
comment.
Journal of the American College of Cardiology Vol. 43, No. 2, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.11.005
thrombotic model has remained difficult to trace defini-
tively. Within the zone of no-reflow, discrete ultrastructural
abnormalities are observed, suggesting anatomic damage to
the microvasculature (Fig. 1). Diffuse and regional endo-
thelial swelling with bleb-like structures appear to occlude
the capillaries. Endothelial gaps, fibrin tactoids, rouleaux
formation, neutrophil plugging, and compression of capil-
laries from adjacent swollen myocytes have been identified
(1–3). Spasm of the microvasculature at the pre-capillary
level also has been implicated (19). However, in our studies
of mechanical non-thrombotic occlusion of the coronary
artery, ultrastructural identification of platelet or platelet
plugs within the microvasculature was an extremely rare
finding (1). In the present study, the authors also indicated
to me that on histologic analysis they did not observe
platelet plugging of the microvasculature either in control or
treated animals. If this is the case, then why should a GP
IIb/IIIa inhibitor work? One explanation is that inhibition
of platelet activation prevents or reduces the release of
injurious vasoactive and chemotactic mediators from plate-
lets that may exacerbate tissue injury (11). For example,
inhibition of chemotactic mediators might prevent neutro-
phils from entering the area, thereby reducing damage due
to neutrophil-mediated oxygen free-radical release. Of note,
in one previous study from our laboratory, Przyklenk et al.
(20) showed that oxygen free-radical scavengers given at the
time of reperfusion reduced no-reflow as assessed by radio-
active microspheres. Inhibiting platelet release of vasoactive
mediators theoretically could reduce microvascular spasm,
although recently we observed that two agents known to
reduce vascular spasm, adenosine and verapamil, did not
prevent no-reflow in a similar non-thrombotic model (21).
Another possible explanation is that GP IIb/IIIa inhibitors
reduce infarct size by some mechanism independent of
platelet inhibition and that this is followed by a secondary
reduction in no-reflow.
Nevertheless, the fact that Kunichika et al. (11) found
that GP IIb/IIIa inhibition reduced no-reflow as well as
infarct size in this non-thrombotic model is a fascinating
observation. It suggests that the role of platelets in inducing
no-reflow, even in a model in which the coronary artery
occlusion is created with a mechanical device or snare rather
than thrombus, may be far more important than previously
appreciated.
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